Zacks Investment Research upgraded shares of Female Health (NASDAQ:VERU) from a sell rating to a hold rating in a report published on Friday morning.
According to Zacks, “Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. “
VERU has been the subject of several other research reports. HC Wainwright set a $5.00 target price on shares of Female Health and gave the company a buy rating in a report on Tuesday, March 6th. ValuEngine upgraded shares of Female Health from a sell rating to a hold rating in a report on Thursday, March 1st.
Female Health (NASDAQ:VERU) last announced its quarterly earnings results on Wednesday, February 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.03). Female Health had a negative net margin of 73.11% and a negative return on equity of 17.63%. The business had revenue of $2.59 million during the quarter, compared to the consensus estimate of $5.30 million. research analysts forecast that Female Health will post -0.14 earnings per share for the current fiscal year.
In other Female Health news, Director Harry Fisch purchased 24,000 shares of the company’s stock in a transaction on Wednesday, March 7th. The stock was acquired at an average price of $1.62 per share, for a total transaction of $38,880.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mitchell Shuster Steiner purchased 20,000 shares of the company’s stock in a transaction on Friday, March 16th. The stock was acquired at an average price of $1.96 per share, with a total value of $39,200.00. The disclosure for this purchase can be found here. Insiders purchased a total of 119,000 shares of company stock valued at $210,980 in the last quarter. 37.00% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This story was reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3377185/female-health-veru-upgraded-to-hold-by-zacks-investment-research.html.
Female Health Company Profile
Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Female Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health and related companies with MarketBeat.com's FREE daily email newsletter.